Market Intelligence, Clinical Progress, and High-Purity Reagents for Multiple Myeloma and Autoimmune Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD48 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD48 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CD48 Products |
| Gene Delivery | CD48 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry validation. |
View CD48 Products |
| Benchmark Ab | Anti-CD48 Recombinant Antibody Sequence derived from clinical benchmark (e.g., SGN-CD48A analogue) as positive control. |
View CD48 Products |
| Validator | CD48 siRNA Set For knockdown verification in target-specificity assays. |
View CD48 Products |
| Related Target A | CD244 (2B4) High-affinity native ligand for CD48. Crucial for blocking/neutralization assay setups. |
View CD244 Products |
| Related Target B | SLAMF7 (CS1) Closely related SLAM family member. Essential for selectivity and off-target screening panels. |
View SLAMF7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cynomolgus/rodent evaluation | Human, Mouse, and Cynomolgus CD48 ortholog proteins available with >95% purity. |
| SLAM family subfamily off-target screening | Homolog panel proteins (SLAMF1-F7) strictly verified by mass spectrometry and SDS-PAGE. |
| Lack of reliable positive controls | Clinical benchmark biosimilar antibodies included in the catalog. |
| False positive signal validation | Sequence-verified siRNA included for target knockdown and specificity confirmation. |
Live CD48 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD48 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and bispecific constructs. CD48 (also known as SLAMF2) is highly expressed on plasma cells in multiple myeloma (MM) and on various immune cells, making it a highly attractive but complex target. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific epitopes and tuning affinity to avoid hematological toxicity (such as lymphopenia and anemia) caused by pan-immune cell binding.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Seagen (SGN-CD48A, historical benchmark), Academic Institutions | Multiple Myeloma, Lymphoma | Internalization Assay (Need high-purity HEK293-expressed ECD-Fc for conjugation validation) |
| Bispecific Antibodies | Biotech Startups, Immunotherapy Developers | Hematological Malignancies, Autoimmune Diseases | Dual-binding Affinity Testing (Need cross-reactive CD48 and CD3/CD244 antigens) |
| Monoclonal Antibodies (mAbs) | Clinical-stage Biopharma | Graft-versus-Host Disease (GvHD), SLE | Ligand Blocking Assay (Need high-purity CD48 and CD244/2B4 proteins) |